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Background:  In  2007,  Ontario  implemented  a  school-based  human  papillomavirus  (HPV)  vaccination  pro-
gram  targeting  grade  8  girls.  Girls  may  complete  the  series  in  grade  9 (extended  eligibility).  Limitations
in  the  existing  provincial  data  sources  for  assessing  HPV  vaccine  coverage  in  Ontario  prompted  the  use
of two surveys  of  Health  Units  (HUs)  to  calculate  provincial  vaccine  coverage  for  the  ﬁrst  three  years  of
the vaccination  program.
Methods:  We  surveyed  Ontario’s  36 HUs  in March  and  November  2011  to  obtain  vaccine  coverage  infor-
mation,  including  source  of denominator  data,  and  use  of  local  information  systems.  The  second  survey
was necessary  in order  to assess  coverage  including  extended  eligibility  for  the  third  year.  HU-reported
HPV  vaccine  coverage  was  compared  to coverage  estimates  obtained  from  two  provincial  systems:  the
Immunization  Records  Information  System  (IRIS)  and  the HPV  reimbursement  database,  a system  used
to remunerate  HUs  for HPV  vaccine  doses  administered.
Results: 100%  of  HUs  participated  in  the  two surveys.  The  provincial  coverage  estimates  using HU-reported
data  were:  51%  (2007–2008),  58%  (2008–2009),  and  59%  (2009–2010)  with  large  variation  by  HU. Cov-
erage  increased  signiﬁcantly  over  time.  The  number  of  HUs  that were  able  to  report  on  doses  given  as
part of  extended  eligibility  also  increased  over  time  (47%  in  2007–2008  to 89%  in  2009–2010;  p =  0.0008).
Comparisons  across  the  three  data  sources  (survey,  IRIS  and  reimbursement  database)  revealed  signiﬁ-
cantly  different  coverage  estimates.  Class  or school  lists  were  the  most  common  source  of  denominator
data  used  by  HUs  (27/36,  75%),  however  independent  schools  were  not  included  by  all.
Conclusions:  As not  all HUs  were  able  to report  on HPV  vaccine  coverage  including  extended  eligibility
doses  these  ﬁndings  likely  underestimate  the  true  coverage  attained  by  Ontario’s  program.  Although
coverage  is  below  the  Canadian  Immunization  Committee  benchmark  of 80%  within  two  years  of  program
implementation,  the upward  trend  in  coverage  is encouraging.. Introduction
In 2007, the Canadian Immunization Committee (CIC) rec-
mmended that publicly-funded human papillomavirus (HPV)
accination programs aim for 80% and 90% series coverage of
emales in a single grade cohort (grades 4–8) within two  and ﬁve
ears of program implementation, respectively [1].  The Canadian
rovince of Ontario (population 13 million) implemented a vol-
ntary, publicly-funded, school-based HPV vaccination program,
sing the quadrivalent HPV vaccine in the 2007–2008 school year.
he program targets grade eight girls (approximately 13 years of
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age). It did not include a catch-up program; however, it has a
one-year extended eligibility component. This entitles girls who
receive at least one dose of publicly-funded vaccine before enter-
ing grade nine (before September 1) to complete the series in grade
nine.
Data associated with Ontario’s school-based HPV vaccina-
tion program are collected in two  information systems: the
Immunization Records Information System (IRIS) and the HPV
reimbursement database (Table 1). Ontario does not have a com-
prehensive immunization registry; however, Ontario legislation [2]
requires that all public health departments (health units [HUs])
maintain a record of immunization for all school pupils in their
jurisdiction. IRIS is the decentralized database used for this purpose.
Open access under CC BY-NC-ND license.It is used to assess coverage locally and to contribute to provin-
cial coverage assessment for vaccines administered in infancy,
childhood, and Ontario’s three school-based programs (quadriva-
lent meningococcal conjugate, hepatitis B and HPV). Healthcare
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Table  1
Public health information systems in Ontario for HPV vaccine coverage assessment.
Immunization Records Information System (IRIS) HPV  reimbursement database (HPVRD)
Participation 100% of HUs 100% of HUs
Purpose Immunization coverage of school pupils Financial reimbursement for doses
administered to the target population
Numerator data Individual-level Aggregate by dose number and birth yeara
Numerator extraction By birth year By birth yeara
Extended eligibility doses included in numerator No Can be imputed using various assumptions
Includes doses given by HCPs Only if information received by HU Includes doses released to HCPsb
Mechanism to speciﬁcally report on doses given by HCPs No Yes, but cannot use to determine series
completionb
Source of denominator data Imported by HU into system Imported by HU into system
Routine data analysis for coverage Yes No
Nature of database Decentralized (requires data extraction by HU with
transfer to MOHLTC)
Centralized (MOHLTC can extract data)
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a By grade in 2007–2008.
b System contains the total number of doses released to HCPs but not by dose nu
roviders (HCPs) do not have access to IRIS but doses administered
y HCPs are entered into IRIS, when parents provide this informa-
ion to local HUs. The IRIS database is associated with a number
f well-recognized limitations [3].  It contains information on birth
ear and not grade. This is problematic for a school-based program
uch as HPV, where eligibility is based on grade. It also makes it dif-
cult to calculate coverage including doses administered as part of
he extended eligibility program. The HPV vaccine reimbursement
atabase (HPVRD) is used by HUs to receive ﬁnancial remunera-
ion for HPV vaccine doses administered by HU staff. The HPVRD
ay  also be used to assess HPV vaccine coverage although it is not
peciﬁcally designed for this purpose. HUs input local denominator
stimates into both systems, but without a consistent methodol-
gy. Our previous contact with Ontario VPD managers through a
rocess evaluation of the program suggested that many HUs use a
ariety of systems to monitor their local HPV vaccine coverage, in
he setting of these challenges [4].
As part of a comprehensive HPV vaccine program evaluation, we
ndertook an assessment of series (i.e., three dose) coverage for the
chool-based vaccination program’s ﬁrst three years. Our objectives
ere [1] to calculate provincial vaccine coverage using a survey
hat would permit HUs to report data they felt best reﬂected local
overage; [2] to examine the source of denominator data used to
stimate the vaccine program’s target population; and [3] to obtain
eedback on local methods for HPV vaccine coverage assessment.
. Materials and methods
.1. Program implementation
The program is locally administered by Ontario’s 36 HUs; these
Us vary greatly in population size from approximately 34,000
o 2.7 million. Schools disseminate and collect locally developed
nformed consent forms and provide appropriate facilities within
he school (e.g. gymnasiums, libraries) for student vaccination.
ursing staff employed by HUs administer the vaccine to eligible
emale students at schools within their jurisdiction. HU staff input
ata into IRIS to update the immunization status of students who
eceived the HPV vaccine. Some HUs do this immediately following
chool-based clinics, while others update IRIS at the conclusion of
he school year and use alternate data systems to track doses as
hey are administered during the school year. On a monthly basis,
Us input the aggregate number of doses administered at school-
ased clinics through the HPVRD to receive remuneration. Data on
oses administered as part of the program are maintained by local
Us and not by schools, school boards or the Ontario Ministry of
ducation.Although it is a school-based program, in select scenarios doses
of publicly-funded HPV vaccine are released to HCPs, but the vast
majority of doses are administered by HU staff. For example, an
average of 351 doses were released annually to local HCPs over
the ﬁrst three program years. These doses are reported through
the HPVRD. It is expected that these doses would still be captured
within HU estimates of local vaccine coverage.
Although all grade 8 girls in the province are eligible, some inde-
pendent schools and two  publicly-funded Catholic school boards
have declined to participate in school-based HPV vaccination clin-
ics over the three year period [4].  These students must attend a
vaccine clinic held at their local HU if they want to be immunized.
3. Surveys of Ontario HUs
We  e-mailed individualized surveys to each of the Vaccine Pre-
ventable Disease (VPD) managers at Ontario’s 36 HUs in March
2011. The survey’s content included: a request for coverage esti-
mates for the program’s ﬁrst three years (including numerator and
denominator data); as well as questions on denominator source
and use of information systems to monitor HPV vaccine coverage.
In the March 2011 survey, vaccine coverage data both inclu-
sive and exclusive of doses associated with the extended eligibility
program component were requested for program years 1 and 2,
and exclusive of extended eligibility doses for year 3, as this pro-
gram component was still underway (ending in August 2011). A
follow-up survey was  disseminated in November 2011 request-
ing coverage data inclusive of extended eligibility doses for year
3 only. The surveys were not pilot-tested prior to dissemination
due to time constraints. Completed surveys were returned by fax
or electronically.
4. Data sources used to individualize surveys
In addition to standardized questions, each HU received HPV
vaccine coverage estimates calculated centrally for their own HU
from IRIS and HPVRD. To provide context for our questions about
local denominator estimation, we provided HUs with three differ-
ent estimates of series HPV vaccine coverage for the 2007–2008
program year which varied according to denominator source. To
calculate these coverage estimates, we used HU-speciﬁc numera-
tor data (including extended eligibility doses) from the HPVRD for
2007–2008 and used denominator estimates for 2007–2008 from
the following three sources: the HPVRD; population projections
from the 2006 Canadian Census; and Ontario Ministry of Education
(MoEd) school enrolment data for grade 8 females enrolled in pub-
lic and independent schools within their HU boundaries. Of note,
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Table 2
Numerator and denominator data, and resulting 3 dose HPV vaccine coverage estimates by program year and survey.
Program year Date of survey Proportion of HUs with numerator data
including extended eligibility doses (n = 36)
Numerator Denominator Coverage
2007–2008 March 2011 47% 38,827 76,113 51%
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2009–2010 March 2011 n/a 
2009–2010 December 2011 89% 
Us routinely receive school enrollment data directly from local
chool boards, and/or schools. In contrast, data from the MoEd was
peciﬁcally requested by our team and assigned to individual HUs
sing geographic information system (GIS) techniques.
. Analysis of survey data
Survey data were entered into Microsoft Excel 2010. Quanti-
ative data were analysed using Excel and SAS (Version 9.2). A
hematic content analysis was performed for qualitative responses
5].
Provincial denominator estimates were calculated from the sur-
ey by summing denominator data provided by the HUs across
ll 36 HUs for each program year. Provincial HPV vaccine cover-
ge estimates were calculated by dividing the summed numerator
ata by the summed denominator data for each program year. Data
rom HUs who were and were not able to provide information
n doses administered as part of the extended eligibility program
ere combined rather than examined separately in order to best
pproximate current provincial coverage. Coverage was  calculated
ased on the school-year during which the series was initiated,
ather than completed. Students did not need to complete the series
ithin a pre-speciﬁed time (i.e. six months) in order to be consid-
red complete.
Chi-squared tests were used to compare coverage estimates
etween and within data sources for each program year and to
ompare the proportion of HUs able to report on coverage includ-
ng extended eligibility over time. The Cochran–Armitage trend test
as used to assess linear trends in coverage over time from the
urveys.
We considered coverage and denominator estimates from HU
urveys to be the gold standard when comparing survey responses
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Fig. 1. Three dose HPV vaccine coverage for 2009–2010 program year (including 45,102 77,291 58%
38,776 71,762 54%
44,146 74,340 59%
to other data sources. To explore the potential impact of alter-
nate denominator estimates on provincial HPV vaccine coverage,
we conducted a sensitivity analysis using the survey as the source
of numerator data and three different sources of denominator data:
survey, MoEd, and the 2006 Canadian Census. Ninety-ﬁve percent
conﬁdence intervals were constructed around these provincial cov-
erage estimates.
6. Results
6.1. HPV vaccine coverage
All 36 (100%) HUs participated in each of the two surveys.
According to internal HU estimates from the surveys, Ontario’s
HPV vaccine coverage for its school-based program was  calcu-
lated as: 51% (2007–2008), 58% (2008–2009), and 59% (2009–2010)
(Table 2). There was large variation in coverage by HU, for each
program year. The range in coverage by HU was 35–69% in year 1,
44–73% in year 2, and 38–76% in year 3. Fig. 1 depicts the range
in coverage, including extended eligibility doses where possible,
for year 3 by HU. Increasing numbers of HUs were able to report
on doses given as part of extended eligibility over time with 17/36
(47%) reporting these doses in year 1, 21/36 (58%) in year 2, and
32/36 (89%) in year 3. This increase was  statistically signiﬁcant
(p = 0.0008).
Coverage data from IRIS was incomplete in the ﬁrst two years
with 35/36 HUs (2007–2008) and 34/36 HUs (2008–2009) pro-
viding data to the MOHLTC. The two  non-participating HUs in
2008–2009 were Ontario’s two largest HUs with a combined size
of 3.9 million, or 31% of Ontario’s population. In year 3, all 36 HUs
provided HPV vaccine coverage data to IRIS, although one small HU
reported only 1% coverage. Despite these limitations, when using
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Ontario Health  Unit
extended eligibility doses where possible), by 36 Health Units and Ontario.
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Fig. 2. Provincial HPV vaccine coverage (3 doses) by year and data source.
RIS data provincial HPV vaccine coverage was calculated to be 48%
or year 1, 52% for year 2, and 55% for year 3. These coverage esti-
ates do not include doses administered to grade nine students as
art of the extended eligibility program due the current method-
logy of IRIS data extraction. All 36 HUs reported data on coverage
hrough the HPVRD for each of the three program years. Analy-
is of the reimbursement database yielded the following coverage
stimates for Ontario: 59% in 2007–2008 (including extended eligi-
ility); 54% in 2008–2009 (including extended eligibility); and 49%
n 2009–2010 (extended eligibility data were not available).
Fig. 2 displays the coverage estimates for the ﬁrst three program
ears, by data source. Within each year, differences in coverage
etween data sources were signiﬁcant (p < 0.0001). Statistical test-
ng using the Cochran–Armitage trend test found a statistically
igniﬁcant trend towards increasing coverage over time from the
urveys (p < 0.0001).
The inﬂuence of different denominator sources on HPV vaccine
overage revealed that across all three program years, coverage was
ighest when using HU-reported denominators collected through
he survey, and lowest when using the provincial population pro-
ections from the 2006 Canadian Census (Table 3). Within each
ear, the coverage estimates produced by the various denominator
ources were signiﬁcantly different.
. Survey responses on local coverage calculation
.1. Source of denominator data
The most common source of denominator data used by HUs to
stimate their target population were class or school lists, reported
y 27/36 (75%) of HUs. Five to six HUs (depending on program
ear) used multiple data sources to arrive at the denominator used
or coverage, one of which typically involved class or school lists.
wo HUs indicated that schools that do not participate in the pro-
ram are speciﬁcally excluded from their denominator. Another
U reported that independent schools are not included in their
enominator.
A similar number of HUs (26/36, 72%) reported that their pre-
erred source of denominator data for future coverage assessments
s class/school lists or school board enrolment. An additional six
ndicated that the MoEd was their preferred source. Among the 26
Us reporting class/school lists or school board enrolment as the
referred option, ﬁve expressed this with speciﬁc caveats. These
ncluded: the denominator should also include home-schooled
tudents (n = 2) and private school attendees (n = 2); certain girls 31 (2013) 757– 762
should be removed from the denominator, speciﬁcally previously
immunized students (n = 2) or those with medical contraindications
(n = 1).
7.2. Information systems for HPV vaccine coverage
Three-quarters of HUs (27/36) indicated they use the HPVRD to
monitor HPV vaccine coverage, followed by Excel software (26/36,
72%), and IRIS (23/36, 64%). Eight HUs (22%) reported using one
information system, 13 (36%) use two systems; 11 (31%) use three
systems and four (11%) use four or more.
8. Discussion
Using two  surveys of Ontario HUs, provincial coverage estimates
for the ﬁrst three years of the HPV vaccine program were calculated
as: 51% (2007–2008), 58% (2008–2009), and 59% (2009–2010),
with substantial variation among HUs. As not all HUs reported
on extended eligibility, these ﬁgures are underestimates of the
true coverage attained by the program. These coverage estimates
remain below the CIC benchmark of 80% within two  years of
program implementation, although the upward trend is encour-
aging. They are also markedly lower than the coverage of other
school-based programs in Ontario. In 2007–2008, coverage among
school-based hepatitis B and meningococcal conjugate vaccine pro-
grams (targeting grade 7 students) were 80% and 86%, respectively
[5]. Ontario’s HPV vaccine coverage for its school-based program is
similar to that of provinces from central and western Canada. For
the ﬁrst two years of program implementation, three dose coverage
amongst these provinces ranged from 60–63% in British Columbia
[6,7], 50–60% in Alberta, 58–66% in Saskatchewan, and 52–61% in
Manitoba [8].  In contrast, higher coverage has been observed in
provinces east of Ontario including Quebec (80–86%) and the mar-
itime provinces of Newfoundland, Nova Scotia and Prince Edward
Island (85%) [8]. Coverage data from the territories have not been
publicly reported to date. Canadian HPV vaccination programs tar-
get a range of grades with some provinces and territories offering
catch-up programs [9].
International HPV vaccine coverage data (series completion)
is also heterogeneous. In the United States, coverage among girls
aged 13–17 years was 32% in 2010 [10]. Coverage estimates among
European countries where HPV vaccine is included in the national
immunization schedule ranges from 17% (Norway) to 81% (United
Kingdom) [11]. European programs target a range of adolescent
ages and with the exception of Austria, all target females only
[11]. European countries implement the programs either through
school-based delivery and/or public health service delivery and
some require co-payment for vaccine; in Austria full payment by
the vaccinee is required [11]. Countries with established school-
based programs tend to have higher HPV vaccine coverage than
countries without such programs [12].
The reasons for Ontario’s less than optimal coverage are likely
complex and have been partially explored through a process eval-
uation of the program [2],  and by investigations at the HU level
[13,14]. The process evaluation which interviewed Ontario HU staff
identiﬁed a rapid program roll-out (e.g. program announcement in
August 2007 for implementation in the 2007–2008 school year) and
intense and often negative media scrutiny as possible factors [2].
Ontario coverage data are not currently available by school board
which would allow us to explore the impact of school-based, versus
clinic-based, HPV vaccination on coverage, particularly in jurisdic-
tions where HU staff were not permitted into schools. The unique
aspect of Ontario’s history with its HPV vaccination program as it
relates to Catholic school board participation merits further con-
sideration. In Ontario, two publicly-funded Catholic school boards
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Table 3
Impact of denominator source on 3 dose HPV vaccine coverage estimates by program year.
Program year Date of survey Survey Numerator Source of denominator Denominator Coverage
estimate
95% Conﬁdence
Interval
2007–2008 March 2011 38,827 Survey 76,113 51.0% 50.7–51.4%
38,827 Ministry of Education 79,069 49.1% 48.8–49.5%
38,827 Canadian Census 81,025 47.9% 47.6–48.3%
2008–2009 March 2011 45,102 Survey 77,291 58.4% 58.0–58.7%
45,102 Ministry of Education 78,918 57.2% 56.8–57.5%
45,102 Canadian Census 80,320 56.2% 55.8–56.5%
2009–2010 December 2011 44,146 Survey 74,340 59.4% 59.0–59.7%
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ave each refused to participate in school-based vaccination clin-
cs; one board in year 1 (the board has permitted clinics since year
), and the other board since year 2 [2].  In the HU with the non-
articipating school board in year 1, coverage increased from 54%
n year 1 to 72% and 71% in years 2 and 3, respectively. In the
ther HU, coverage was 47% in year 1 when it is Catholic school
oard permitted school-based clinics. Coverage changed minimally
nce the board no longer permitted clinics to 45% (year 2) and
4% (year 3); however, it is noteworthy that in other areas of the
rovince coverage increased with time. In both these HUs, there
re other school boards which have participated without disrup-
ion. The ethical dimensions of school boards, entirely funded by
ublic tax dollars, refusing to participate in a publicly-funded vac-
ination program have garnered little public debate in Ontario. One
tep towards improving equitable access to publicly-funded HPV
accination, which may  in turn affect coverage, is ensuring that all
ublicly-funded school boards participate in the program.
In addition to improving coverage, an equally important pro-
ram priority is to implement an accurate and consistent method
or future coverage evaluations. The three major issues identi-
ed through this assessment relate to denominator estimation, the
mportance of including extended eligibility doses and challenges
ue to the lack of a comprehensive immunization registry. Because
he program is grade-based rather than age-based, calculating the
rogram’s target population is complex, as standard denominator
ources (i.e. census data) provide imperfect estimates. Although
ost girls in grade eight would be 13 years of age, some are older
r younger because of being held back or advanced, respectively.
ur sensitivity analysis demonstrated that provincial coverage was
owest when using population projections from the 2006 Canadian
ensus to estimate the denominator size. The survey revealed less
ariability in the source of denominator data than we  expected.
he majority of HUs (27/36, 75%) use class or school lists to esti-
ate the local population of grade eight girls. However, several
Us do not include independent school pupils and two indicated
hat pupils of non-participating schools were removed from their
enominator. This could potentially explain our ﬁnding that cover-
ge estimates were highest when using HU-reported denominator
ata. All HUs should be encouraged to include girls attending inde-
endent schools, home schools, and non-participating schools in
heir denominators. Excluding such schools falsely raises coverage
stimates.
As Ontario does not have a comprehensive immunization reg-
stry, IRIS is the information system currently used to assess
he immunization status of school pupils, despite several well-
ecognized limitations [3].  Our ﬁnding that that 15 HUs (42%)
eported using 3 or more systems to monitor HPV vaccine cov-
rage suggests that the use of IRIS alone does not currently meet
ocal needs. The ﬁnding that an increasing number of HUs were able
o report on extended eligibility doses over time, may  reﬂect the
mplementation of alternate and supplemental data systems. Toof Education not available n/a n/a
 Census 80,672 54.7% 54.4–55.1%
address the limitations of IRIS, Ontario plans to implement a new
centralized electronic system for tracking immunization of school
pupils (Panorama) in 2014–2015. It is hoped that this will result in
improved coverage assessment in the future.
The strengths of this coverage assessment include the participa-
tion of 100% of Ontario HUs and the use of multiple data sources to
assess HPV vaccine coverage. However, there are several limitations
to note. First, it would have been preferable if the survey had con-
tained greater detail about the MoEd as a denominator data source.
Several HUs listed MoEd as their preferred data source, but in sub-
sequent comments revealed that they were referring to class lists
provided by school boards. In addition, the survey did not ask HUs
whether their denominator source included independent school
pupils. Several HUs ﬂagged this as a speciﬁc issue in their com-
ments regarding denominator identiﬁcation. A ﬁnal limitation is
that because less than 100% of HUs were able to report on extended
eligibility doses administered in any program year, this prevented
us from comprehensively assessing the incremental impact of this
program component on coverage.
9. Conclusions
Although HPV vaccine coverage has improved since the program
was initiated in the 2007, we  found that only 59% of grade eight girls
in Ontario completed the vaccine series in the program’s third year.
As in many other jurisdictions, further work remains to be done to
improve HPV vaccine coverage. Until a comprehensive immuniza-
tion registry is implemented, determining the most appropriate
method for assessing HPV vaccine coverage remains an important
program priority for Ontario.
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